ALLIANCES (Sanofi) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2018	Dec. 31, 2011
Alliances Statement [Line Items]
Net product sales									$ 11,660	$ 12,304	$ 13,654
Alliance and other revenues									4,219	4,081	3,967
Total Revenues	4,258	3,921	3,889	3,811	4,441	4,065	4,048	3,831	15,879	16,385	17,621
Equity in net income of affiliates									(107)	(166)	(183)
Other (income)/expense									210	205	(80)
Distribution (to)/from Sanofi - Noncontrolling interest									49	(29)	740
Noncontrolling interest	131				82				131	82	15		(89)
Avapro Avalide [Member]
Alliances Statement [Line Items]
Total Revenues									211	231	503
Sanofi [Member] | Avapro Avalide [Member] | Active Pharmaceutical Ingredient Supply Arrangements [Member]
Alliances Statement [Line Items]
Alliance and other revenues									90	116	117
Sanofi [Member] | Avapro, Avalide, and Plavix [Member]
Alliances Statement [Line Items]
Payment from Sanofi related to restructuring of the alliance agreement												200
Net product sales									102	153	2,930
Alliance and other revenues									317	336	120
Total Revenues									419	489	3,050
Cost of products sold - Cost of product supply									2	4	81
Cost of products sold - Royalties									4	4	530
Other (income)/expense										(18)	(171)
Noncontrolling interest - pre-tax									38	36	844
Sanofi [Member] | Territory Covering Americas and Australia [Member] | Avapro, Avalide, and Plavix [Member]
Alliances Statement [Line Items]
Controlling interest ownership percentage	50.10%								50.10%
Noncontrolling interest ownership percentage	49.90%								49.90%
Royalty revenue									223	220
Development and opt-out royalty income											143
Development royalty expense									2	2	67
Distribution (to)/from Sanofi - Noncontrolling interest									(49)	43	(742)
Noncontrolling interest	38				49				38	49
Sanofi [Member] | Territory Covering Europe and Asia [Member] | Avapro, Avalide, and Plavix [Member]
Alliances Statement [Line Items]
Controlling interest ownership percentage	50.10%								50.10%
Noncontrolling interest ownership percentage	49.90%								49.90%
Previously deferred profit recognized upon restructuring of an alliance agreement										22
Equity in net income of affiliates									(146)	(183)	(201)
Distributions from Sanofi - Noncontrolling interest									153	149	229
Investment in affiliates	32				43				32	43
Net sales									360	395	1,077
Gross profit									297	319	453
Net income									292	313	394
Sanofi [Member] | Territory Covering Europe and Asia [Member] | Avapro, Avalide, and Plavix [Member] | Discovery Royalties [Member]
Alliances Statement [Line Items]
Cost of products sold									32	38	133
Sanofi [Member] | Territory Covering Europe and Asia [Member] | Avapro, Avalide, and Plavix [Member] | Receivables And Payables Net Cash Distributions Intercompany Balances [Member]
Alliances Statement [Line Items]
Current assets and current liabilities	$ 94				$ 108				$ 94	$ 108	$ 293